有趣的是,以前接受过抗BCMA治疗的患者有类似的反应率(ORR为25%)人们对联合疗法的毒性没有出现新的担忧。伊伯多米-地塞米松联合其他抗骨髓瘤药物如卡非佐米(NCT05199311,NCT02773030)、伊沙佐米(NCT04998786)、环磷酰胺(NCT04392037)和idecabtagene Vicleucel(Karmma...
Effect of methylprednisolone on transforming growth factor-beta, insulin-like growth factor-I, and basic fibroblast growth factor gene expression in the ki... The present study was carried out to determine whether transforming growth factor-β, insulin-like growth factor-I and basic fibroblast growth...
今年对60名美国血液学家的调查显示,若valoctocogene roxaparvovec顺利获批,预计在一年内将有29%的Hemliba患者和34%的凝血因子VIII患者转为基因治疗。 参考来源:BioMarin Receives Complete Response Letter (CRL) from FDA for Valoctocogene Roxaparvovec ...
the results clearly indicate that the either the gene specific marker used in the present study or linked SSR marker Satt228 can be efficiently used in the selection of target plants carrying null al...